

Message

From: Stefan Hristu [/O=THERANOS ORGANIZATION/OU=FIRST ADMINISTRATIVE GROUP/CN=RECIPIENTS/CN=SHRISTU]
Sent: 2/24/2009 6:48:08 PM
To: Elizabeth Holmes [eholmes@theranos.com]
CC: Carolyn Balkenhol [cbalkenhol@theranos.com]
Subject: Theranos studies completed to date

Novartis – Bone inflammation study
 TNF-alpha, IL-6, CRP
 Recent analysis yielded new information
 GSK – metabolic retrospective study
 Active GLP-1
 Eliminated the need for a lab
 BMS – metabolic retrospective study
 Active GLP-1
 Great feedback, Home run
 Merck – metabolic retrospective study
 Active GLP-1
 Great correlation with Merck data
 Mayo – metabolic live study
 Active GLP-1
 Whole blood time course in live subject
 Stanford Study – inflammation study in AML patients
 CRP, protein-C
 Monitoring biomarkers for neutropenic fever in hospitalized chemotherapy patients
 Great results, trends correlate with physical events, such as fever spikes, etc.
 Pfizer – at TNONC SCRI – angiogenesis study
 VEGF, VEGFR2, PLGF
 Deployed instruments to fourth line cancer patients in poor and underdeveloped areas of TN
 Celgene – Revlimid and tumor flare
 Screening of 18 biomarkers and statistical analysis of results
 Reduced the number of relevant biomarkers to only a few that can now be placed on cartridges for a future study
 Novartis – RA inflammation in children
 CRP
 Study is currently wrapping up
 AstraZeneca – Apoptosis in Healthy volunteers
 M30, m65, nDNA
 Follow-up whole blood reproducibility study
 AstraZeneca / University of Manchester – Angiogenesis in cancer patients
 VEGF, VEGFR2, PLGF
 Retrospective plasma and “live” whole blood
 Very promising results
 Follow-up whole blood reproducibility study

Attached is in slide format already - slide 3. Let me know if this is what you were looking for. As far as I know, this is the complete list.

Stefan Hristu
 Client Solutions Lead
 Theranos, Inc.
 Worldwide +1.650.644.5241

US Toll-Free 1.877.843.4180
Fax +1.650.838.0153

=====

PRIVILEGED AND CONFIDENTIAL COMMUNICATION

IMPORTANT : This electronic transmission, and any files transmitted with it are confidential and/or legally privileged information. This information is intended solely for the use of the individual or entity to which it is addressed. Any disclosure, retransmission, reproduction, dissemination or other use of the contents of this information by persons or entities other than the intended recipient is strictly prohibited. If you have received this email in error, please contact us immediately and delete all copies. Please note that any views or opinions presented in this email are solely those of the author and do not necessarily represent those of Theranos, Inc. Finally, before opening or using attachments the recipient should check this email and any attachments for the presence of viruses. Theranos, Inc. accepts no liability for any damage caused by any virus transmitted by this email. Our sole responsibility is limited to resupplying any affected attachments.

=====


File Produced in Native Format



Where in the world is Theranos™ ?

This presentation and its contents are Theranos proprietary and confidential.

Geography to Date



Completed Successes

Novartis – Bone inflammation study

- TNF-alpha, IL-6, CRP
- Recent analysis yielded new information

GSK – metabolic retrospective study

- Active GLP-1
- Eliminated the need for a lab

BMS – metabolic retrospective study

- Active GLP-1
- Great feedback, Home run

Merck – metabolic retrospective study

- Active GLP-1
- Great correlation with Merck data

Mayo – metabolic live study

- Active GLP-1
- Whole blood time course in live subject

Stanford Study – inflammation study in AML patients

- CRP, protein-C
- Monitoring biomarkers for neutropenic fever in hospitalized chemotherapy patients
- Great results, trends correlate with physical events, such as fever spikes, etc.

Pfizer – at TNONC SCRI – angiogenesis study

- VEGF, VEGFR2, PLGF
- Deployed instruments to fourth line cancer patients in poor and underdeveloped areas of TN

Celgene – Revlimid and tumor flare

- Screening of 18 biomarkers and statistical analysis of results
- Reduced the number of relevant biomarkers to only a few that can now be placed on cartridges for a future study

Novartis – RA inflammation in children

- CRP
- Study is currently wrapping up

AstraZeneca – Apoptosis in Healthy volunteers

- M30, m65, nDNA
- Follow-up whole blood reproducibility study

AstraZeneca / University of Manchester – Angiogenesis in cancer patients

- VEGF, VEGFR2, PLGF
- Retrospective plasma and “live” whole blood
- Very promising results
- Follow-up whole blood reproducibility study

Ongoing

AZ programs

- Apoptosis
 - Healthy Volunteers
 - Investigating baseline of m30, m65, nDNA biomarkers
- Angiogenesis
 - In patients with solid tumors, working with Royal Marsden Hospital
 - In patients with cancer, working with University of Manchester, UK

Mayo clinic

- Active and Total GLP-1
 - 300 patients
 - 2600 samples to be run in house
 - Will result in publication of Theranos™ System results

Centocor

- Asthma (ENA-78, Rantes, Eotaxin, TARC, IgE, asthma drug)
 - Assay development for pK/pD
 - To be deployed after completion into Phase 1b FIH study

Theranos 001-2009

- Sepsis in healthy population to support 510(k) submission
 - Protein-C, CRP
 - Currently undergoing IRB review and hoping for fast track approval

Celgene

- Statistical model for Bone and Hematopoietic regulation based on historical data and literature

Future Fun - The beginning

Centocor

- Phase 1B FIH study using Theranos™

Celgene

- Revlimid method of action model development from field data gathered using Theranos™ Systems
- Validate Bone and Hematopoietic models using field data gathered using Theranos™ Systems; ACE-011 drug MOA

Schering-Plough

- TNF-alpha and IL-6 validation
 - Once completed, Theranos™ Systems will be deployed in studies for gathering field data

Mayo clinic

- Total and active GLP-1 system to be used for future projects to replace traditional lab methods

Astra Zeneca

- Angiogenesis and Apoptosis

Royal Marsden

- Angiogenesis on Theranos systems across entire organization

Daiichi-Sankyo

- TNF-alpha, IL-6 validations

Merck

TBI and PTSD with Gov, DoD, NIH, work with HMOs, POC monitoring, 510(k)

2009 : Ox

prosperity through fortitude and hard work

World-Class Organization

Quality

Products

Software

Sales and Service

Business Development

Intellectual Property